James Larkin
Melanoma and kidney cancer trialist who co-led CheckMate 067, the trial with 10-year immunotherapy survival data.
James Larkin was a lead investigator of CheckMate 067 (nivolumab plus ipilimumab in melanoma) and CheckMate 9ER in renal cell carcinoma, shaping first-line immunotherapy in both diseases.
| Title | Journal | Year |
|---|---|---|
| Five-year survival with combined nivolumab and ipilimumab in advanced melanoma (CheckMate 067) | NEJM | 2019 |
Before 2011 median survival in metastatic melanoma was under a year; this trial shows that roughly half of patients treated with combination checkpoint blockade are now long-term survivors, effectively cured. It anchors first-line treatment of advanced melanoma and sets the benchmark for every new regimen, including nivolumab-relatlimab. The combination's toxicity means nivolumab alone or newer doublets remain reasonable for some patients.
For patients with advanced melanoma, immunotherapy offers a realistic chance of long-term survival and probably cure, and the ten-year data show that patients who are alive and progression-free at three years rarely die of melanoma afterwards. Nivolumab plus ipilimumab gives the best long-term results but at a high price in serious side effects; nivolumab alone or nivolumab plus relatlimab are alternatives for patients at lower risk or with autoimmune concerns. The trial is also a caution about surrogate endpoints: the survival plateau took years to become visible.
Pages like this
not linked directly; found by shared links- PersonF. Stephen Hodi
Shares CheckMate 067, CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later, CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma, Ipilimumab.
- TrialRELATIVITY-047
Shares CheckMate 067, CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later, Nivolumab, Melanoma.
- TrialCOSMIC-313
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- TermSarcomatoid differentiation (RCC)
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- InstitutionIstituto Nazionale Tumori IRCCS Fondazione G. Pascale
Shares CheckMate 067, Ipilimumab, Nivolumab, Melanoma.
- TrialCheckMate 214
Shares Ipilimumab, Nivolumab, Renal cell carcinoma.
- InstitutionWest German Cancer Center (WTZ), University Hospital Essen
Shares CheckMate 067, Ipilimumab, Nivolumab, Melanoma.
- Key paperASCO 2021 guideline: how to recognise and manage the immune-related side effects of checkpoint inhibitors
Shares CheckMate 067 at ten years: half of melanoma patients treated with nivolumab plus ipilimumab were alive a decade later, Ipilimumab, Nivolumab, Melanoma.